THE IMPROVEMENT OF LIPID-LOWERING THERAPY EFFECTIVENESS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND CONCOMITANT LIVER DISEASE (RESULTS OF ADDITIONAL ANALYSIS OF THE RAKURS STUDY)

Aim. To evaluate the differences between a group of patients treated with ursodeoxycholic acid (UDCA) during the study period and a group of patients not treated with UDCA by pseudo-randomization using Propensity Score Matching.Material and methods. 262 patients aged 60.1±8.9 years, taking statins f...

Full description

Saved in:
Bibliographic Details
Main Authors: N. P. Kutishenko, S. Yu. Martsevich, O. V. Lerman, I. S. Balashov, V. A. Nevzorova, I. I. Reznik, G. V. Shavkuta, D. A. Yakhontov
Format: Article
Language:English
Published: Столичная издательская компания 2015-09-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/95
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849228034277638144
author N. P. Kutishenko
S. Yu. Martsevich
O. V. Lerman
I. S. Balashov
V. A. Nevzorova
I. I. Reznik
G. V. Shavkuta
D. A. Yakhontov
author_facet N. P. Kutishenko
S. Yu. Martsevich
O. V. Lerman
I. S. Balashov
V. A. Nevzorova
I. I. Reznik
G. V. Shavkuta
D. A. Yakhontov
author_sort N. P. Kutishenko
collection DOAJ
description Aim. To evaluate the differences between a group of patients treated with ursodeoxycholic acid (UDCA) during the study period and a group of patients not treated with UDCA by pseudo-randomization using Propensity Score Matching.Material and methods. 262 patients aged 60.1±8.9 years, taking statins for the secondary prevention of cardiovascular complications were included into a 6-month observational cohort study. The UDCA intake was recommended to all the patients due to the presence of liver and/or bile duct diseases. One part of the patients strictly followed medical recommendations and used UDCA, while the other part of the patients wasn’t taking UDCA. This allowed comparing the effect of UDCA in these groups.Results. Propensity Score Matching method allowed forming two groups of patients of 52 people each with similar main clinical and demographic characteristics. A more significant decrease in the levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) (up to 4.0 mmol/L and 1.92 mmol/L, respectively; p<0.001) after 6 months was found in patients treated with lipid-lowering therapy in combination with UDCA as compared with patients without UDCA (up to 4.52 mmol/L and 2.6 mmol/L, respectively; p<0.05). No ALT, AST, CPK, LDH activity deterioration and no bilirubin serum level increase was found. Due to statin treatment the target levels of LDL-C by the end of the study were achieved in 31% of the patients of UDCA-group. Target levels of LDL-C were not achieved in any of the patients of the group without UDCA (p<0.001). There was demonstrated a high adherence to UDCA therapy.Conclusion. Combined therapy with statins and UDCA is effective and safe in patients with high cardiovascular risk and concomitant liver disease. Co-administration of statins with UDCA is promising in the treatment of hyperlipidemia in patients with low tolerance to statins. However, additional controlled studies are required.
format Article
id doaj-art-9ec3f2f720fe42ab89f3a2cc2e7c9814
institution Kabale University
issn 1819-6446
2225-3653
language English
publishDate 2015-09-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj-art-9ec3f2f720fe42ab89f3a2cc2e7c98142025-08-23T10:00:16ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-0111329730310.20996/1819-6446-2015-11-3-297-30394THE IMPROVEMENT OF LIPID-LOWERING THERAPY EFFECTIVENESS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND CONCOMITANT LIVER DISEASE (RESULTS OF ADDITIONAL ANALYSIS OF THE RAKURS STUDY)N. P. Kutishenko0S. Yu. Martsevich1O. V. Lerman2I. S. Balashov3V. A. Nevzorova4I. I. Reznik5G. V. Shavkuta6D. A. Yakhontov7State Research Centre for Preventive MedicineState Research Centre for Preventive MedicineState Research Centre for Preventive MedicineState Research Centre for Preventive Medicine, I.M. Sechenov First Moscow State Medical UniversityVladivostok State Medical UniversityUral State Medical AcademyRostov State Medical UniversityNovosibirsk State Medical UniversityAim. To evaluate the differences between a group of patients treated with ursodeoxycholic acid (UDCA) during the study period and a group of patients not treated with UDCA by pseudo-randomization using Propensity Score Matching.Material and methods. 262 patients aged 60.1±8.9 years, taking statins for the secondary prevention of cardiovascular complications were included into a 6-month observational cohort study. The UDCA intake was recommended to all the patients due to the presence of liver and/or bile duct diseases. One part of the patients strictly followed medical recommendations and used UDCA, while the other part of the patients wasn’t taking UDCA. This allowed comparing the effect of UDCA in these groups.Results. Propensity Score Matching method allowed forming two groups of patients of 52 people each with similar main clinical and demographic characteristics. A more significant decrease in the levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) (up to 4.0 mmol/L and 1.92 mmol/L, respectively; p<0.001) after 6 months was found in patients treated with lipid-lowering therapy in combination with UDCA as compared with patients without UDCA (up to 4.52 mmol/L and 2.6 mmol/L, respectively; p<0.05). No ALT, AST, CPK, LDH activity deterioration and no bilirubin serum level increase was found. Due to statin treatment the target levels of LDL-C by the end of the study were achieved in 31% of the patients of UDCA-group. Target levels of LDL-C were not achieved in any of the patients of the group without UDCA (p<0.001). There was demonstrated a high adherence to UDCA therapy.Conclusion. Combined therapy with statins and UDCA is effective and safe in patients with high cardiovascular risk and concomitant liver disease. Co-administration of statins with UDCA is promising in the treatment of hyperlipidemia in patients with low tolerance to statins. However, additional controlled studies are required.https://www.rpcardio.online/jour/article/view/95dyslipidemiahigh cardiovascular riskstatinsliver disordersursodeoxycholic acidsafety of the therapypropensity score matching analysis
spellingShingle N. P. Kutishenko
S. Yu. Martsevich
O. V. Lerman
I. S. Balashov
V. A. Nevzorova
I. I. Reznik
G. V. Shavkuta
D. A. Yakhontov
THE IMPROVEMENT OF LIPID-LOWERING THERAPY EFFECTIVENESS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND CONCOMITANT LIVER DISEASE (RESULTS OF ADDITIONAL ANALYSIS OF THE RAKURS STUDY)
Рациональная фармакотерапия в кардиологии
dyslipidemia
high cardiovascular risk
statins
liver disorders
ursodeoxycholic acid
safety of the therapy
propensity score matching analysis
title THE IMPROVEMENT OF LIPID-LOWERING THERAPY EFFECTIVENESS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND CONCOMITANT LIVER DISEASE (RESULTS OF ADDITIONAL ANALYSIS OF THE RAKURS STUDY)
title_full THE IMPROVEMENT OF LIPID-LOWERING THERAPY EFFECTIVENESS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND CONCOMITANT LIVER DISEASE (RESULTS OF ADDITIONAL ANALYSIS OF THE RAKURS STUDY)
title_fullStr THE IMPROVEMENT OF LIPID-LOWERING THERAPY EFFECTIVENESS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND CONCOMITANT LIVER DISEASE (RESULTS OF ADDITIONAL ANALYSIS OF THE RAKURS STUDY)
title_full_unstemmed THE IMPROVEMENT OF LIPID-LOWERING THERAPY EFFECTIVENESS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND CONCOMITANT LIVER DISEASE (RESULTS OF ADDITIONAL ANALYSIS OF THE RAKURS STUDY)
title_short THE IMPROVEMENT OF LIPID-LOWERING THERAPY EFFECTIVENESS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND CONCOMITANT LIVER DISEASE (RESULTS OF ADDITIONAL ANALYSIS OF THE RAKURS STUDY)
title_sort improvement of lipid lowering therapy effectiveness in patients with high cardiovascular risk and concomitant liver disease results of additional analysis of the rakurs study
topic dyslipidemia
high cardiovascular risk
statins
liver disorders
ursodeoxycholic acid
safety of the therapy
propensity score matching analysis
url https://www.rpcardio.online/jour/article/view/95
work_keys_str_mv AT npkutishenko theimprovementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT syumartsevich theimprovementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT ovlerman theimprovementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT isbalashov theimprovementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT vanevzorova theimprovementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT iireznik theimprovementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT gvshavkuta theimprovementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT dayakhontov theimprovementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT npkutishenko improvementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT syumartsevich improvementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT ovlerman improvementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT isbalashov improvementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT vanevzorova improvementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT iireznik improvementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT gvshavkuta improvementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy
AT dayakhontov improvementoflipidloweringtherapyeffectivenessinpatientswithhighcardiovascularriskandconcomitantliverdiseaseresultsofadditionalanalysisoftherakursstudy